Objective: To assess Australian psychiatrists' and psychiatry trainees' knowledge of and attitudes towards psychedelics as treatment for psychiatric disorders.
Method: Australian members of the Royal Australian and New Zealand College of Psychiatrists were invited to participate in an anonymous survey that ran from October 1 to November 30 2021. Participants were asked about their knowledge of the risks and benefits of, and attitudes towards, psychedelics, including the factors that influence those attitudes.
Results: Fifty-one doctors responded to the survey, and 38 completed all items. The majority were male, consultants and based primarily in New South Wales. Respondents reported awareness of the evidence demonstrating the benefits of psychedelics for most disorders; however most respondents, particularly females, perceived psychedelics as risky. Most considered themselves open-minded and believed psychedelics deserved further research.
Conclusions: The poor response rate was a major limitation of this study. Our sample of Australian psychiatrists and trainees were enthusiastic about psychedelics as psychiatric treatment and were aware of some of the evidence demonstrating their efficacy. Safety continues to be a concern, despite growing evidence of their safety in therapeutic settings. Education about the evidence of their efficacy and the risks associated with their use is needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10398562231155125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experimental Test of Perceptions of Psychedelics by Therapeutic and Recreational Use.
J Psychoactive Drugs
January 2025
Department of Psychology, Washington State University Vancouver, Vancouver, WA, USA.
Recent research on the potential therapeutic value of psychedelic substances has led to changes in media representation and drug policy in some U.S. states.
View Article and Find Full Text PDFTowards a dynamic processual model of psychedelic microdosing.
Int J Drug Policy
December 2024
School of Sociology, Philosophy and Anthropology, University of Exeter, UK. FF16, Byrne House, Streatham Drive, Exeter, EX4 4AP, UK. Electronic address:
Background: Existing research highlights an increase in psychedelic microdosing, particularly for therapeutic purposes and as a means for self-enhancement. However, we know little about the different routes into and out of microdosing, particularly by those who do not consume other illicit substances, and of the processes involved in the development, maintenance, and cessation of practices.
Methods: Drawing upon a trans-national interview-based study of 23 participants actively microdosing (n = 19), about to start (n = 3), or who were past users (n = 1), we develop a phased-based analysis of different user pathways.
Health Care Workers' Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review.
J Palliat Med
December 2024
Caritas Christi and Department of Psychosocial Cancer Care, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Recent research indicates that psychedelic-assisted therapy (PAT) may be a safe and effective treatment for several psychiatric disorders, including those experienced by people with serious physical illness. Understanding health care workers' (HCWs') attitudes and knowledge about the clinical application of psychedelics for patients with serious illness is important in progressing research and identifying factors to consider in potential future implementation of PAT. The aim of this systematic review was to synthesize quantitative, qualitative, and mixed methods studies that explored HCWs' attitudes and knowledge about the role of psychedelics in treating psychological distress in patients with serious illness.
View Article and Find Full Text PDFCannabinoids and the male reproductive system: Implications of endocannabinoid signaling pathways.
Maturitas
January 2025
School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, Victoria 3000, Australia. Electronic address:
The escalating use and legalization of cannabis (marijuana) in the United States reflect shifting societal attitudes and growing awareness of its potential therapeutic benefits. Historically viewed as a harmful psychoactive substance, contemporary research has shown the intricate pharmacology of cannabis, with its diverse array of cannabinoids and their interactions with the endocannabinoid system. Among these cannabinoids, Δ9-tetrahydrocannabinol is the primary psychoactive component, characterized by its activation of cannabinoid receptors.
View Article and Find Full Text PDFSurvey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Addict Sci Clin Pract
November 2024
Department of Psychiatry, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA.
Article Synopsis
- There is increasing interest in using psychedelics for therapy, but there's limited research on how peer recovery coaches feel about using them for substance use disorder (SUD) treatment.
- A survey conducted in Massachusetts gathered data from 146 peer recovery coaches regarding their demographics, substance use history, and attitudes toward psychedelics in addiction treatment.
- While many coaches showed support for psychedelics in treating SUD, those with 12-step program experience were more cautious about potential risks, while those with personal psychedelic use history were more supportive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!